Chromosomal translocations involving the T Cell Receptor (TCR) loci represent one of the most recurrent oncogenic hallmarks of T-cell acute lymphoblastic leukaemia (T-ALL) and are generally believed to result from illegitimate V(D)J recombination events. However, molecular characterization and evaluation of the extent of recombinase involvement at the TCR-oncogene junction has not been fully evaluated. Screening for TCRβ and TCRα/δ translocations by FISH and LM-PCR in 280 T-ALLs allowed identification of four unreported TCR translocated oncogene partners (GNAG, LEF1, NKX2-4 and IL2RB). Molecular mapping of genomic junctions from TCR translocations showed that the majority of oncogenic partner breakpoints are not recombinase mediated and that the regulatory elements predominantly used to drive oncogene expression differ markedly in TCRβ (exclusively enhancer driven) and TCRα/δ translocations, when use of an enhancer-independent cryptic internal promoter is frequent. Our data also imply that oncogene activation takes place at a very immature stage of thymic development, when Dδ2-Dδ3/Dδ3-Jδ1 and Dβ-Jβ rearrangements occur, whereas the bulk leukemic maturation arrest occurs at a much later (cortical) stage. These observations have implications for T-ALL therapy, since the "pre-leukemic" early thymic clonogenic population needs to be eradicated and its disappearance monitored.
Introduction
T-cell Acute Lymphoblastic Leukemias (T-ALL) are malignant proliferations of T-cell precursors arrested at various stages of development 1, 2 . Understanding of T-ALL oncogenesis has advanced rapidly over the last decade and numerous combinations of multigenic aberrations and oncogenic synergy have been identified 3 . Amongst these, chromosomal translocations involving the T Cell Receptor (TCR) loci represent the recurrent oncogenic hallmark of T-ALL 4 . TCR translocations predominantly involve the TCRα/δ locus at chromosome (chr.) 14q11 or TCRβ at chr. 7q34, but rearrangement of TCRγ at chr. 7p15 is virtually unrecognized 4 .
Such translocations are generally believed to result from illegitimate V(D)J recombination events, and to lead to ectopic activation of oncogenes, due to their the potent positive regulatory elements of the TCR locus or loss of Negative Regulatory Element (NRE) 5, 6 .
Specific mechanistic differences in V(D)J-mediated translocation mechanisms have been
shown to guide break location and clustering in T-ALL 7 . Two main types of oncogenic translocations involving the TCRβ and TCRα/δ have been described 8 . In so-called "type 1"
translocations (Supplementary Figure S1 ), a cryptic but functional Recombination Signal Sequence (cRSS) is present near the oncogene, and is mistakenly targeted by the RAG recombinase as a partner for a recombining TCR gene segment. Translocations of this type consequently cluster (within tens of bp) at this cryptic site. In type 2 translocations, only the Ig/TCR locus breaks are generated by RAG targeting, and the translocation results from repair mistakes between TCR rearranging intermediates and DNA breaks in the vicinity of the oncogene. One distinctive feature of the two mechanisms is that the former involves DNA transactions between 2 breaks (4 DNA ends) both of which are thought to be recombinasemediated, while the latter involves DNA transactions between 3 breaks (6 DNA ends) with only the TCR breaks being due to recombinase activity. In T-ALL, the basis for DNA breakage at the other breakpoint is largely unknown, is probably heterogeneous, and is not necessarily specific to lymphoid malignancies. It is generally considered that both the TCR locus and the partner oncogene need to be in an accessible chromatin configuration in order to undergo translocation. Since TCR rearrangements occur sequentially in a highly coordinated fashion during both normal and leukemic T lymphoid development, molecular characterisation of TCR translocations can throw light on the timing of the oncogenic event.
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From
In humans, the earliest T cell precursor was defined as CD34+/CD7+/CD45RA+/sCD3-/CD2-/CD5-/CD1a- 9 . Progressive lineage restriction and acquisition of T-cell potential following migration from the bone marrow to the thymus is likely to involve successive differentiation into CD5+, CD1a-T/NK precursors, followed by definitive T-cell commitment of CD34+, sCD3-CD4/8 double negative (DN) thymocytes at the CD5+, CD1a+ developmental stage 10 . This is followed by appearance of intermediate Several significant T-ALL oncogenes, including TLX1 (10q24), HOXA (7p15), LMO2
(11p13), LMO1 (11p15), TAL1 (1p32) or NOTCH1 (9q34) were identified from TCR chromosomal translocation analysis 13, 14 . A recent, but unique, FISH study demonstrated that TCR-oncogene translocations detected karyotypically are largely underestimated, notably those involving TCRβ, which were detected in 19% of 126 T-ALLs 4 . The TCR partner oncogene was not identified in several cases. Similarly, molecular characterization and evaluation of the extent of recombinase involvement at the TCR-oncogene junction has not been fully evaluated in T-ALL. We have recently shown that some oncogenes can influence the type of TCRδ rearrangements which have leukaemogenic potential, since TLX1 overexpression inhibits the TCRα enhanceosome and therefore leads to auto-extinction of TCR-TLX1 translocated cells in which the TCRα enhancer is on the same chromosome as TLX1 15 .
In this study, we searched for TCRβ and TCRα/δ translocations by FISH and LM-PCR in 280 T-ALL and characterized their molecular junctions. We confirm the high incidence of TCRβ translocations in both adult and pediatric T-ALLs and have identified four unreported TCR oncogene partners. We also show that the majority of oncogene partner breakpoints are not recombinase mediated and that the regulatory elements predominantly used to drive oncogene expression differ in TCRβ (exclusively enhancer driven) and TCRα/δ translocations, when use of an enhancer-independent cryptic internal promoter is frequent.
Patients and methods

T-ALL samples
Diagnostic samples from a consecutive series of T-ALLs from 280 patients, 128 pediatric and 152 adults (16 years or over), were screened for TCRβ and TCRα/δ rearrangement by FISH and/or LM-PCR. Sample collection and analyses were obtained with informed consent in accordance with the Declaration of Helsinki with approval from institutional review boards of institutions that participated in this study. Diagnosis of T-ALL was based on the World Health Organization 2008 criteria, defined by expression of cytoplasmic and/or surface CD3, and negativity of CD19 and MPO, as reported 1 . The only criterion for inclusion in the study was the availability of appropriate material for cytogenetic/molecular analysis.
Immunophenotyping, molecular marker identification of STIL-TAL1 (also known as SIL-TAL1) and PICALM-MLLT10 (also known as CALM-AF10) fusion transcripts, oncogene quantification (TLX1, TLX3, LMO1, LMO2, TAL1, HOXA9) and TCR immuno-genotyping were performed as described 1, 16 .
Cytogenetic and FISH analysis
Cytogenetic analysis with R-banding was performed at various institutions on metaphases from bone marrow (BM) aspirates taken at diagnosis, using standard procedures. Karyotypes were described according to the International System for Human Cytogenetic Nomenclature (ISCN, 2005) .
Screening by FISH for TCRβ and TCRδ rearrangements was performed at Necker Hospital.
We designed a dual color probe using RP11-114L10 and RP11-1084E14 BAC clones for RP11-1008P23 and RP11-1018M13 (LMO2), RP11-159M21 and RP11-1112E24 (TAL1), and RP11-1136C8 and 1132K14 (HOXA).
Ligation Mediated PCR (LM-PCR) and sequencing
LM-PCR assays were performed as described 17, 18 . Briefly, 330ng of genomic DNA was digested using a combination of six blunt end restriction enzymes (DraI, PvuII, StuI, SmaI, SspI and EcoRV). For the TCRβ-based LM-PCR rounds, ligation of 50pmol of an adaptor to both ends of the restriction fragments was followed by two rounds of PCR using nested adaptor-specific (AP1 and AP2) oligonucleotide primers, as well as Dβ1, Dβ2, Jβ1.6 and Jβ2.7 oligonucleotide primers. The LM-PCR products were sequenced in both directions, using the specific primer and the nested adaptor specific primer (AP2). The sequences were blasted to the NCBI nucleotide database (http://www.ncbi.nlm.nih.gov/BLAST) and Ensembl genome browser (http://www.ensembl.org/Multi/blastview). Junctions identified by LM-PCR were validated with a specific primer set flanking the identified breakpoint.
Quantitative RQ-PCR
We used a TaqMan assay to quantify HOXA9, LMO2, and TAL1 transcripts with the 
Extra-Chromosomal Recombination Assay
Briefly, since previously described 19 , a recombination plasmid (Supplementary Figure S7A) in which the two sequences to be tested for V(D)J recombination are separated by a termination signal was constructed. The The TCRβ-LEF1 translocated case was a cortical CD1a+/pre-αβ adult T-ALL (T-ALL439, Table 1 , this case also demonstrated a novel TCRα/δ-NKX2-4 translocation, see below). LM-PCR analysis identified the breakpoints within intron 3 of LEF1 ( Figure 1A ). Interestingly this TCRβ-LEF1 translocation leads to the LEF1 transcript inactivation as RT-PCR analysis of the full length LEF1 transcript (Exons 1-11) demonstrated that the wild-type full length LEF1 transcript was not detectable ( Figure S2A ) and SNP-6 CGH-array analysis of this case confirmed that the un-translocated LEF1 allele harboured partial intragenic deletion ( Figure   S2B ). These data are in line with the reported tumor suppressor function of LEF1 in T-cell oncogenesis 21 . The TCRβ-IL2RB translocated T-ALL was a cortical CD1a+/pre-αβ pediatric T-ALL with a normal karyotype (N°17, Table 1 ). Molecular breakpoint mapping revealed that the translocation put the ILR2B gene under the control of the TCRβ Enhancer (Eβ) ( Figure   1B ).
TCRα/δ translocation screening and oncogene partner identification in adult and pediatric
T-ALLs
Of 280 T-ALLs, 38 (13%) demonstrated a TCRα/δ translocation by cytogenetic and FISH analysis. These were more frequent in adults (29/152, 19%) compared to pediatric (9/128, 7%) cases (p=0.002). As for the TCRβ translocated cases, only 15/30 TCRα/δ translocated TALLs with available karyotypic data harbored a 14q11 abnormalities (Table 2) .
LM-PCR and/or dual color FISH allowed identification of 36 oncogene partners from these 38 split-TCRα/δ T-ALLs (Table 2) Table 2 and Figure 1D ), demonstrated a karyotypic t(9;10;14)(q22;q23;q11). On the basis of LM-PCR results and the overexpression of TLX1, we performed three-color FISH analysis using a combination of TLX1 (red), GNAQ (yellow) and TCRα/δ (green) probes. We demonstrated a fusion of GNAQ and TCRα/δ, GNAQ and TLX1, on the der(9) and der(10), respectively. However FISH analysis on the der(14) revealed a complex rearrangement and a fusion on 14q, of, sequentially, TLX1, GNAQ, and TCRα/δ (telomere to centromere). By LM-PCR it was possible to identify the GNAQ-TCRα/δ junction ( Figure 1D ) but not the TLX1 junction(s).
Another case (T-ALL500) showed a translocation with three partners including TLX1, TCRδ and TCRβ, confirmed by three-color FISH analysis (Supplementary Figure S4) . during early thymic-cell differentiation in the vast majority of both adult and pediatric cases 23 . These data also imply that oncogene activation takes place at an immature DN/CD1a -/CD34 + stage of thymic development, when Dδ2-Dδ3/Dδ3-Jδ1 and Dβ-Jβ rearrangements occur, whereas the bulk leukemic maturation arrest occurs at a later (cortical) stage. This strongly suggests that most TCR-oncogene translocations correspond to early "driver" events in T-ALL oncogenesis.
Most TCR partner oncogene breakpoints appeared to not be recombinase mediated
Since all TCRβ junctions identified involved DNA transactions between 3 breaks (6 DNA ends, type 2), the breaks in the oncogene partner are unlikely to be recombination signal sequence (RSS) mediated. This was also the case for the majority of TCRα/δ-oncogene Figure S5) , which might be compatible with a type 1 translocation followed by rare ongoing recombination of the SJ (leading to a pseudo-HJ 25 ). Unfortunately, neither LM-PCR assays nor direct PCR attempts to identify the expected reciprocal TLX/Dβ coding joint on Der7 gave rise to amplification products, preventing definitive resolution of this case. Case T-ALL86 is even more complex, and compatible with a rare variant involving the collusion between a type 1 synapse (Dδ2-12/TAL1) and a Dδ2-Dδ3 rearrangement 26 .
In order to explore whether CpG dinucleotides are involved in the type 2 translocations identified here (as described in the BCL2 MBR, BCL1 MTC and the TCF3 clusters to be hotspots for translocation breakpoints in B lymphoid lymphomas and leukemias ( Figure 3) . In all remaining cases (20/24) the oncogene and Eα/δ were not on the same derivative chromosome, demonstrating that oncogene overexpression must be due to distinct regulatory elements within the TCRδ locus.
Virtually all of the TCRα/δ-TLX1 breakpoints were within the TLX1 Exon 1 (5' to the ATG start site and 3' to the promoter), leading to separation of the TLX1 promoter from the coding region. In order to determine the origin of TCR driven TLX1 transcripts, we performed clono-
specific RT-PCR across the breakpoints of both TCRα/δ-TLX1 and TCRβ-TLX1
translocations. "Fusion transcripts" (resulting from transcription within the TCRα/δ locus) were detected in all the TCRα/δ-TLX1 samples ( Figure 4A ), but not in the TCRβ-TLX1 samples (not shown and as previously described 15 . suggesting the presence of positive regulatory element(s) upstream to the TCRδ locus which drives TLX1 over-expression. By contrast, in cases with TCRα/δ-LMO2 or TCRα/δ-TAL1 translocations with the same configuration, no fusion transcripts from the TCRδ locus could be identified ( Figure 4B ).
These data demonstrate that the mechanisms driving oncogene deregulation other than by downstream enhancer juxtapositioning are different in TLX1+ and TLX1-T-ALL.
The levels of LMO2, TAL1 and TLX1 expression did not differ depending on whether expression was driven by Eβ, Eα or upstream TCRδ regulatory elements (or cryptic promoters), demonstrating that sufficient levels of transcriptional deregulation are likely to be required for oncogenic clonal selection ( Figure 4C ). In line with this observation, breakpoints were scatted, often at a significant distance from the oncogene, in Enhancer-driven (Eβ or Eα) TCR-oncogene cases. In contrast, they clustered close to the oncogene when the oncogene and Eα/δ were located on different derivative chromosomes, in keeping with promoter dependant cis-acting positive regulatory elements (Figures 2 and 3) .
Overall, these data demonstrate that Enhancer-independent oncogene deregulation and clonal selection occurs frequently in TCRα/δ, but not in TCRβ translocations in T-ALL. . IL2RB is constitutively expressed in mature T-cells and is induced by TCR activation, leading to proliferation and T-cell survival 29 A confusing situation may however arise when the type 1 signal joint, generated on one of the derivative chromosomes, keeps on rearranging with IG/TCR partners in cis. This may indeed create a pseudo-hybrid joint (ΨHJ) between a TCR/IG coding-end and the cRSS, but in which both rearranging partners (the coding-end and the cRSS) undergo processing (deletion, P, and N regions) 35 . Although this two-step mechanism has to date rarely been reported 25 
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ALL therapy, since the "pre-leukemic" early thymic clonogenic population needs to be eradicated and its disappearance monitored.
A two-step model of translocation has been proposed based on a TCRβ-TAL2 translocation model: first, a cRSS located 3' to TAL2 reacts with Dβ1 in the thymus of a healthy individual and then a Dβ1-Jβ2.7 rearrangement occur which leads to TAL2 overexpression 25 . This mechanism is not compatible with the majority of TCRβ translocations described here, since Dβ1 and Jβ segments are not on the same derivative.
While all breaks from TCRβ-oncogene translocations mapped 3' to the oncogene, the vast majority of breaks from TCRα/δ-oncogenes translocations mapped 5' to the oncogene.
Consequently, although oncogene activation in TCRβ translocated cases was consistent with classical TCRβ Enhancer β-mediated activation, the TCRα/δ translocations uncoupled the oncogene and Eα onto two distinct derivative chromosomes, implying a distinct deregulation mechanism (involving potential non-enhancer regulatory elements in the TCRδ promoter region). We have demonstrated that TLX1 leads to inhibition of the TCRα enhancer, via an ETS1 interaction 15 , leading to counter-selection of translocations which juxtapose TLX1 and the TCRα enhancer in cis. It is therefore possible that the different types of translocations observed for other T-ALL oncogenes are also impacted by the consequences of oncogene expression on juxtaposed TCR regulatory elements.
Remarkably, despite the obvious contrast in the mechanisms of oncogenes activation (see TLX1 or LMO2 in Figure 4C ), no significant differences could be observed in oncogene overexpression levels from TCRβ and TCRα/δ translocation configurations, suggesting oncogenic selection of cases with sufficient/optimal expression levels. This suggests distinct molecular mechanisms of oncogene activation with respect to the TCR locus orientation involved in the translocation rather than the oncogene itself and justifies further investigation in the molecular mechanisms of early oncogenic deregulation.
In conclusion, the majority of TCR structural translocations in T-ALL have now probably been identified, but the mechanisms leading to chromosomal break and mis-repair on the partner chromosome remain unidentified. These translocations occur at an earlier stage than bulk maturation arrest and the localization of TCRβ and TCRα/δ breakpoints differ, probably at least in part due to an impact of the deregulated oncogene on the function of the juxtaposed TCR regulatory elements. 
